In 2023, we expect revenue and earnings development in our business segments as shown in the table below:
Financial Targets by Business Segment 2023
Download(XLS, 35 KB)| Operating Companies1 | Targets 2023 | Fiscal year 2022 |
|---|---|---|
| Fresenius Kabi | ||
| Revenue growth (organic) | Low-to-mid-single-digit percentage growth | €7,850 m |
| EBIT margin | Around 1 percentage point below the structural margin band of 14% – 17% | 13.8% |
| Fresenius Helios | ||
| Revenue growth (organic) | Mid-single-digit percentage growth | €11,716 m |
| EBIT margin | Within the structural margin band of 9% – 11% | 10.1% |
| Investment Companies1 | Targets 2023 | Fiscal year 2022 |
|---|---|---|
| Fresenius Medical Care2 | ||
| Revenue growth (in constant currency) | Low-to-mid-single-digit percentage growth | €19,398 m |
| EBIT growth (in constant currency) | Flat-to-high-single-digit percentage decline | €1,540 m |
| Fresenius Vamed | ||
| Revenue growth (organic) | Low-to-mid-single-digit percentage growth | €2,359 m |
| EBIT margin | Clearly below the structural margin band of 4 – 6% | 0.8% |
| 1 Before special items | ||
| 2 In 2022, operating income was supported by €277 million (at current currency) of U.S. Provider Relief funding (PRF). There is no further receipt of PRF assumed for 2023. To provide a comparable basis for the 2023 earnings outlook, the basis is adjusted accordingly. | ||